Examining the safety of amiodarone

Expert Opinion on Drug Safety

Volumn 11, Issue 2, 2012, Pages 191-214

  Santangeli, Pasquale ^a   Di Biase, Luigi ^a   Burkhardt, John David ^a   Bai, Rong ^a   Mohanty, Prasant ^a   Pump, Agnes ^a   Natale, Andrea ^a  

^a Texas Cardiac Arrhythmia Institute   (United States)

Author keywords

Adverse effects; Amiodarone; Atrial fibrillation; Toxicity

Indexed keywords

AMIODARONE; CYTOCHROME P450 3A4; DEETHYLAMIODARONE; DRONEDARONE; MAGNESIUM; PLACEBO; SOTALOL; VERNAKALANT;

ALCOHOL LIVER DISEASE; ANTIARRHYTHMIC ACTIVITY; ATAXIA; ATRIOVENTRICULAR BLOCK; BIOACCUMULATION; BRADYCARDIA; CONTINUOUS INFUSION; COORDINATION DISORDER; COST EFFECTIVENESS ANALYSIS; DEFIBRILLATOR; DIFFERENTIAL DIAGNOSIS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG FECES LEVEL; DRUG HALF LIFE; DRUG INDICATION; DRUG METABOLISM; DRUG SAFETY; DRUG SCREENING; DRUG URINE LEVEL; DRUG WITHDRAWAL; ECHOGRAPHY; EYE TOXICITY; EYELID INFLAMMATION; FATTY LIVER; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HEADACHE; HEART ARREST; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART DEATH; HEART FAILURE; HEART SURGERY; HEART VENTRICLE ARRHYTHMIA; HORMONE SYNTHESIS; HOSPITALIZATION; HUMAN; HYPOTENSION; INTERSTITIAL PNEUMONIA; INVOLUNTARY MOVEMENT; KERATITIS; LENS DISEASE; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TOXICITY; LOADING DRUG DOSE; LUNG EMBOLISM; LUNG FUNCTION TEST; LUNG TOXICITY; MAINTENANCE DRUG DOSE; MEDLINE; MONOTHERAPY; MORTALITY; NAUSEA; OPTIC NERVE DISEASE; OUTCOME ASSESSMENT; PARESTHESIA; PERIPHERAL NEUROPATHY; PHLEBITIS; PHOTOSENSITIVITY; PHYSICAL EXAMINATION; POSTOPERATIVE COMPLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; RETINOPATHY; REVIEW; RISK REDUCTION; SIDE EFFECT; SINGLE DRUG DOSE; SKIN PIGMENTATION; SKIN TOXICITY; SLOW DRUG RELEASE; SYSTEMATIC REVIEW; THORAX RADIOGRAPHY; THYROID SCINTISCANNING; THYROID TOXICITY; THYROIDITIS; THYROTOXICOSIS; TREMOR; VISUAL DISORDER; VISUAL IMPAIRMENT;

AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; DEATH, SUDDEN, CARDIAC; EVIDENCE-BASED MEDICINE; HUMANS; PATIENT SELECTION; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84857407667     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2012.660915     Document Type: Review

References (148)

1. Singh BN. Amiodarone: historical development and pharmacologic profile. Am Heart J 1983;106(4 Pt 2):788-97 (Pubitemid 13010812)
2. Charlier R, Deltour G, Baudine A, et al. Pharmacology of amiodarone, and anti-anginal drug with a new biological profile. Arzneimittelforschung 1968;18(11):1408-17
3. Singh BN, Vaughan Williams EM. The effect of amiodarone, a new anti-anginal drug, on cardiac muscle. Br J Pharmacol 1970;39(4):657-67
4. Rosenbaum MB, Chiale PA, Halpern MS, et al. Clinical efficacy of amiodarone as an antiarrhythmic agent. Am J Cardiol 1976;38(7):934-44
5. Nattel S, Singh BN. Evolution, mechanisms, and classification of antiarrhythmic drugs: focus on class III actions. Am J Cardiol 1999;84(9A):11R-9R
6. Wellens HJ, Brugada P, Abdollah H, et al. A comparison of the electrophysiologic effects of intravenous and oral amiodarone in the same patient. Circulation 1984;69(1):120-4 (Pubitemid 14215870)
7. Auer J, Weber T, Berent R, et al. A comparison between oral antiarrhythmic drugs in the prevention of atrial fibrillation after cardiac surgery: the pilot study of prevention of postoperative atrial fibrillation (SPPAF), a randomized, placebo-controlled trial. Am Heart J 2004;147(4):636-43 (Pubitemid 38900448)
8. Butler J, Harriss DR, Sinclair M, et al. Amiodarone prophylaxis for tachycardias after coronary artery surgery: a randomised, double blind, placebo controlled trial. Br Heart J 1993;70(1):56-60 (Pubitemid 23243746)
9. Daoud EG, Strickberger SA, Man KC, et al. Preoperative amiodarone as prophylaxis against atrial fibrillation after heart surgery. N Engl J Med 1997;337(25):1785-91 (Pubitemid 28006782)
10. Dorge H, Schoendube FA, Schoberer M, et al. Intraoperative amiodarone as prophylaxis against atrial fibrillation after coronary operations. Ann Thorac Surg 2000;69(5):1358-62 (Pubitemid 30434858)
11. Giri S, White CM, Dunn AB, et al. Oral amiodarone for prevention of atrial fibrillation after open heart surgery, the Atrial Fibrillation Suppression Trial (AFIST): a randomised placebo-controlled trial. Lancet 2001;357(9259):830-6 (Pubitemid 32239367)
12. Guarnieri T, Nolan S, Gottlieb SO, et al. Intravenous amiodarone for the prevention of atrial fibrillation after open heart surgery: the Amiodarone Reduction in Coronary Heart (ARCH) trial. J Am Coll Cardiol 1999;34(2):343-7
13. Harahsheh BS, Sawalha WA. Effect of amiodarone on atrial fibrillation after coronary artery bypass surgery. Saudi Med J 2001;22(9):797-9 (Pubitemid 32975947)
14. Hohnloser SH, Meinertz T, Dammbacher T, et al. Electrocardiographic and antiarrhythmic effects of intravenous amiodarone: results of a prospective, placebo-controlled study. Am Heart J 1991;121(1 Pt 1):89-95
15. Kuralay E, Cingoz F, Kilic S, et al. Supraventricular tachyarrythmia prophylaxis after coronary artery surgery in chronic obstructive pulmonary disease patients (early amiodarone prophylaxis trial). Eur J Cardiothorac Surg 2004;25(2):224-30 (Pubitemid 38125085)
16. Lee SH, Chang CM, Lu MJ, et al. Intravenous amiodarone for prevention of atrial fibrillation after coronary artery bypass grafting. Ann Thorac Surg 2000;70(1):157-61
17. Maras D, Boskovic SD, Popovic Z, et al. Single-day loading dose of oral amiodarone for the prevention of new-onset atrial fibrillation after coronary artery bypass surgery. Am Heart J 2001;141(5):E8
18. Mitchell LB, Exner DV, Wyse DG, et al. Prophylactic Oral Amiodarone for the Prevention of Arrhythmias that Begin Early After Revascularization, Valve Replacement, or Repair: PAPABEAR: a randomized controlled trial. JAMA 2005;294(24):3093-100 (Pubitemid 43016800)
19. Nygard E, Sorensen LH, Hviid LB, et al. Effects of amiodarone and thoracic epidural analgesia on atrial fibrillation after coronary artery bypass grafting. J Cardiothorac Vasc Anesth 2004;18(6):709-14 (Pubitemid 40093647)
20. Redle JD, Khurana S, Marzan R, et al. Prophylactic oral amiodarone compared with placebo for prevention of atrial fibrillation after coronary artery bypass surgery. Am Heart J 1999;138(1 Pt 1):144-50 (Pubitemid 29331135)
21. Treggiari-Venzi MM, Waeber JL, Perneger TV, et al. Intravenous amiodarone or magnesium sulphate is not cost-beneficial prophylaxis for atrial fibrillation after coronary artery bypass surgery. Br J Anaesth 2000;85(5):690-5
22. White CM, Caron MF, Kalus JS, et al. Intravenous plus oral amiodarone, atrial septal pacing, or both strategies to prevent post-cardiothoracic surgery atrial fibrillation: the Atrial Fibrillation Suppression Trial II (AFIST II). Circulation 2003;108(Suppl 1):II200-6 (Pubitemid 37099955)
23. Yagdi T, Nalbantgil S, Ayik F, et al. Amiodarone reduces the incidence of atrial fibrillation after coronary artery bypass grafting. J Thorac Cardiovasc Surg 2003;125(6):1420-5 (Pubitemid 36759244)
24. Yazigi A, Rahbani P, Zeid HA, et al. Postoperative oral amiodarone as prophylaxis against atrial fibrillation after coronary artery surgery. J Cardiothorac Vasc Anesth 2002;16(5):603-6 (Pubitemid 35155276)
25. Pourbaix S, Berger Y, Desager JP, et al. Absolute bioavailability of amiodarone in normal subjects. Clin Pharmacol Ther 1985;37(2):118-23 (Pubitemid 15048964)
26. Weir SJ, Ueda CT. Amiodarone pharmacokinetics. II. Disposition kinetics following subchronic administration in rats. Biopharm Drug Dispos 1987;8(5):449-60 (Pubitemid 17135141)
27. Weir SJ, Ueda CT. Amiodarone pharmacokinetics. I. Acute dose-dependent disposition studies in rats. J Pharmacokinet Biopharm 1986;14(6):601-13 (Pubitemid 17233500)
28. Cairns JA, Connolly SJ, Gent M, et al. Post-myocardial infarction mortality in patients with ventricular premature depolarizations. Canadian amiodarone myocardial infarction arrhythmia trial pilot study. Circulation 1991;84(2):550-7
29. Cairns JA, Connolly SJ, Roberts R, et al. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Lancet 1997;349(9053):675-82 (Pubitemid 27107745)
30. Ceremuzynski L, Kleczar E, Krzeminska-Pakula M, et al. Effect of amiodarone on mortality after myocardial infarction: a double-blind, placebo-controlled, pilot study. J Am Coll Cardiol 1992;20(5):1056-62
31. Julian DG, Camm AJ, Frangin G, et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet 1997;349(9053):667-74 (Pubitemid 27107744)
32. Nicklas JM, McKenna WJ, Stewart RA, et al. Prospective, double-blind, placebo-controlled trial of low-dose amiodarone in patients with severe heart failure and asymptomatic frequent ventricular ectopy. Am Heart J 1991;122(4 Pt 1):1016-21
33. Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med 1995;333(2):77-82
34. Goldschlager N, Epstein AE, Naccarelli G, et al. Practical guidelines for clinicians who treat patients with amiodarone. Practice Guidelines Subcommittee, North American Society of Pacing and Electrophysiology. Arch Intern Med 2000;160(12):1741-8
35. Latini R, Reginato R, Burlingame AL, et al. High-performance liquid chromatographic isolation and fast atom bombardment mass spectrometric identification of Di-Ndesethylamiodarone, a new metabolite of amiodarone in the dog. Biomed Mass Spectrom 1984;11(9):466-71 (Pubitemid 15208748)
36. Santangeli P, Di Biase L, Dello Russo A, et al. Meta-analysis: age and effectiveness of prophylactic implantable cardioverter-defibrillators. Ann Intern Med 2010;153(9):592-9
37. Mathew JP, Fontes ML, Tudor IC, et al. A multicenter risk index for atrial fibrillation after cardiac surgery. JAMA 2004;291(14):1720-9 (Pubitemid 38489894)
38. Aasbo JD, Lawrence AT, Krishnan K, et al. Amiodarone prophylaxis reduces major cardiovascular morbidity and length of stay after cardiac surgery: a meta-analysis. Ann Intern Med 2005;143(5):327-36
39. Crystal E, Connolly SJ, Sleik K, et al. Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis. Circulation 2002;106(1):75-80 (Pubitemid 34747445)
40. Gillespie EL, Coleman CI, Sander S, et al. Effect of prophylactic amiodarone on clinical and economic outcomes after cardiothoracic surgery: a meta-analysis. Ann Pharmacother 2005;39(9):1409-15 (Pubitemid 41197118)
41. Santangeli P, Biase LD, Pelargonio G, et al. The pharmaceutical pipeline for atrial fibrillation. Ann Med 2011;43(1):13-32
42. Bianconi L, Castro A, Dinelli M, et al. Comparison of intravenously administered dofetilide versus amiodarone in the acute termination of atrial fibrillation and flutter. A multicentre, randomized, double-blind, placebo-controlled study. Eur Heart J 2000;21(15):1265-73 (Pubitemid 30487775)
43. Capucci A, Lenzi T, Boriani G, et al. Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension. Am J Cardiol 1992;70(1):69-72
44. Cotter G, Blatt A, Kaluski E, et al. Conversion of recent onset paroxysmal atrial fibrillation to normal sinus rhythm: the effect of no treatment and high-dose amiodarone. A randomized, placebo-controlled study. Eur Heart J 1999;20(24):1833-42
45. Donovan KD, Power BM, Hockings BE, et al. Intravenous flecainide versus amiodarone for recent-onset atrial fibrillation. Am J Cardiol 1995;75(10):693-7
46. Galperin J, Elizari MV, Chiale PA, et al. Efficacy of amiodarone for the termination of chronic atrial fibrillation and maintenance of normal sinus rhythm: a prospective, multicenter, randomized, controlled, double blind trial. J Cardiovasc Pharmacol Ther 2001;6(4):341-50 (Pubitemid 34141819)
47. Galve E, Rius T, Ballester R, et al. Intravenous amiodarone in treatment of recent-onset atrial fibrillation: results of a randomized, controlled study. J Am Coll Cardiol 1996;27(5):1079-82 (Pubitemid 26117695)
48. Peuhkurinen K, Niemela M, Ylitalo A, et al. Effectiveness of amiodarone as a single oral dose for recent-onset atrial fibrillation. Am J Cardiol 2000;85(4):462-5 (Pubitemid 30089622)
49. Vardas PE, Kochiadakis GE, Igoumenidis NE, et al. Amiodarone as a first-choice drug for restoring sinus rhythm in patients with atrial fibrillation: a randomized, controlled study. Chest 2000;117(6):1538-45 (Pubitemid 30413341)
50. Kochiadakis GE, Igoumenidis NE, Parthenakis FI, et al. Amiodarone versus propafenone for conversion of chronic atrial fibrillation: results of a randomized, controlled study. J Am Coll Cardiol 1999;33(4):966-71
51. Blanc JJ, Voinov C, Maarek M. Comparison of oral loading dose of propafenone and amiodarone for converting recent-onset atrial fibrillation. PARSIFAL Study Group. Am J Cardiol 1999;84(9):1029-32 (Pubitemid 29505370)
52. Boriani G, Biffi M, Capucci A, et al. Conversion of recent-onset atrial fibrillation to sinus rhythm: effects of different drug protocols. Pacing Clin Electrophysiol 1998;21(11 Pt 2):2470-4
53. Martinez-Marcos FJ, Garcia-Garmendia JL, Ortega-Carpio A, et al. Comparison of intravenous flecainide, propafenone, and amiodarone for conversion of acute atrial fibrillation to sinus rhythm. Am J Cardiol 2000;86(9):950-3
54. Joseph AP, Ward MR. A prospective, randomized controlled trial comparing the efficacy and safety of sotalol, amiodarone, and digoxin for the reversion of new-onset atrial fibrillation. Ann Emerg Med 2000;36(1):1-9 (Pubitemid 30641458)
55. Moran JL, Gallagher J, Peake SL, et al. Parenteral magnesium sulfate versus amiodarone in the therapy of atrial tachyarrhythmias: a prospective, randomized study. Crit Care Med 1995;23(11):1816-24
56. Camm AJ, Capucci A, Hohnloser SH, et al. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation. J Am Coll Cardiol 2011;57(3):313-21
57. Channer KS, Birchall A, Steeds RP, et al. A randomized placebo-controlled trial of pre-treatment and short- or long-term maintenance therapy with amiodarone supporting DC cardioversion for persistent atrial fibrillation. Eur Heart J 2004;25(2):144-50 (Pubitemid 38112153)
58. Kochiadakis GE, Igoumenidis NE, Marketou ME, et al. Low dose amiodarone and sotalol in the treatment of recurrent, symptomatic atrial fibrillation: a comparative, placebo controlled study. Heart 2000;84(3):251-7
59. Singh BN, Singh SN, Reda DJ, et al. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 2005;352(18):1861-72
60. Piccini JP, Hasselblad V, Peterson ED, et al. Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. J Am Coll Cardiol 2009;54(12):1089-95
61. Le Heuzey JY, De Ferrari GM, Radzik D, et al. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol 2010;21(6):597-605
62. Kochiadakis GE, Igoumenidis NE, Hamilos MI, et al. Long-term maintenance of normal sinus rhythm in patients with current symptomatic atrial fibrillation: amiodarone vs propafenone, both in low doses. Chest 2004;125(2):377-83 (Pubitemid 38223611)
63. Roy D, Talajic M, Dorian P, et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med 2000;342(13):913-20 (Pubitemid 30177051)
64. Villani R, Zoletti F, Veniani M, et al. A comparison between amiodarone and disopyramide in a delayed-release formulation in the prevention of recurrences of symptomatic atrial fibrillation. Clin Ter 1992;140(1 Pt 2):35-9
65. Vitolo E, Tronci M, Larovere MT, et al. Amiodarone versus quinidine in the prophylaxis of atrial fibrillation. Acta Cardiol 1981;36(6):431-44 (Pubitemid 12073854)
66. Investigators AFADS. Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. J Am Coll Cardiol 2003;42(1):20-9
67. Benjamin EJ, Chen PS, Bild DE, et al. Prevention of atrial fibrillation: report from a national heart, lung, and blood institute workshop. Circulation 2009;119(4):606-18
68. Kirchhof P, Auricchio A, Bax J, et al. Outcome parameters for trials in atrial fibrillation: recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association. Europace 2007;9(11):1006-23 (Pubitemid 351773289)
69. Deedwania PC, Singh BN, Ellenbogen K, et al. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators. Circulation 1998;98(23):2574-9 (Pubitemid 29001197)
70. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation-Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet 2000;356(9244):1789-94
71. Hu CL, Jiang H, Tang QZ, et al. Comparison of rate control and rhythm control in patients with atrial fibrillation after percutaneous mitral balloon valvotomy: a randomised controlled study. Heart 2006;92(8):1096-101 (Pubitemid 44125226)
72. Roy D, Talajic M, Nattel S, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008;358(25):2667-77 (Pubitemid 351860859)
73. Singh SN, Poole J, Anderson J, et al. Role of amiodarone or implantable cardioverter/defibrillator in patients with atrial fibrillation and heart failure. Am Heart J 2006;152(5):974-e7-11
74. Tse HF, Lam YM, Lau CP, et al. Comparison of digoxin versus low-dose amiodarone for ventricular rate control in patients with chronic atrial fibrillation. Clin Exp Pharmacol Physiol 2001;28(5-6):446-50
75. Vora A, Karnad D, Goyal V, et al. Control of heart rate versus rhythm in rheumatic atrial fibrillation: a randomized study. J Cardiovasc Pharmacol Ther 2004;9(2):65-73 (Pubitemid 39071591)
76. Epstein AE, Dimarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities. Heart Rhythm 2008;5(6):e1-62
77. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352(3):225-37 (Pubitemid 40110811)
78. Biswas A, Dey SK, Banerjee AK, et al. Low-dose amiodarone in severe chronic heart failure. Indian Heart J 1996;48(4):361-4 (Pubitemid 26328760)
79. Burkart F, Pfisterer M, Kiowski W, et al. Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: basel Antiarrhythmic Study of Infarct Survival (BASIS). J Am Coll Cardiol 1990;16(7):1711-18
80. Connolly SJ, Dorian P, Roberts RS, et al. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. JAMA 2006;295(2):165-71 (Pubitemid 43076435)
81. Doval HC, Nul DR, Grancelli HO, et al. Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Lancet 1994;344(8921):493-8 (Pubitemid 24261565)
82. Elizari MV, Martinez JM, Belziti C, et al. Morbidity and mortality following early administration of amiodarone in acute myocardial infarction. GEMICA study investigators, GEMA Group, Buenos Aires, Argentina. Grupo de Estudios Multicentricos en Argentina. Eur Heart J 2000;21(3):198-205 (Pubitemid 30137804)
83. Garguichevich JJ, Ramos JL, Gambarte A, et al. Effect of amiodarone therapy on mortality in patients with left ventricular dysfunction and asymptomatic complex ventricular arrhythmias: argentine Pilot Study of Sudden Death and Amiodarone (EPAMSA). Am Heart J 1995;130(3 Pt 1):494-500
84. Hamer AW, Arkles LB, Johns JA. Beneficial effects of low dose amiodarone in patients with congestive cardiac failure: a placebo-controlled trial. J Am Coll Cardiol 1989;14(7):1768-74 (Pubitemid 20011873)
85. Hockings BE, George T, Mahrous F, et al. Effectiveness of amiodarone on ventricular arrhythmias during and after acute myocardial infarction. Am J Cardiol 1987;60(13):967-70 (Pubitemid 17164576)
86. Navarro-Lopez F, Cosin J, Marrugat J, et al. Comparison of the effects of amiodarone versus metoprolol on the frequency of ventricular arrhythmias and on mortality after acute myocardial infarction. SSSD Investigators. Spanish Study on Sudden Death. Am J Cardiol 1993;72(17):1243-8 (Pubitemid 23357784)
87. Santangeli P, Dello Russo A, Casella M, et al. Left ventricular ejection fraction for the risk stratification of sudden cardiac death: friend or foe? Intern Med J 2011;41(1a):55-60
88. Connolly SJ, Gent M, Roberts RS, et al. Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 2000;101(11):1297-302 (Pubitemid 30158618)
89. Kuck KH, Cappato R, Siebels J, et al. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest : the Cardiac Arrest Study Hamburg (CASH). Circulation 2000;102(7):748-54 (Pubitemid 30648765)
90. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997;337(22):1576-83
91. The CASCADE study. Cardiac arrest in seattle: conventional versus amiodarone drug evaluation. Am J Cardiol 1991;67(7):578-84
92. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321(6):406-12
93. Reddy VY, Reynolds MR, Neuzil P, et al. Prophylactic catheter ablation for the prevention of defibrillator therapy. N Engl J Med 2007;357(26):2657-65
94. Kuck KH, Schaumann A, Eckardt L, et al. Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease (VTACH): a multicentre randomised controlled trial. Lancet 2010;375(9708):31-40
95. Santangeli P, Di Biase L, Al-Ahmad A, et al. Primary ablation for ventricular tachycardia: when and How? Card Electrophysiol Clin 2011;3(4):675-88
96. Bouvy ML, Heerdink ER, Hoes AW, et al. Amiodarone-induced thyroid dysfunction associated with cumulative dose. Pharmacoepidemiol Drug Saf 2002;11(7):601-6 (Pubitemid 35345412)
97. Martino E, Safran M, Aghini-Lombardi F, et al. Environmental iodine intake and thyroid dysfunction during chronic amiodarone therapy. Ann Intern Med 1984;101(1):28-34 (Pubitemid 14088063)
98. Kennedy RL, Griffiths H, Gray TA. Amiodarone and the thyroid. Clin Chem 1989;35(9):1882-7 (Pubitemid 19242224)
99. Lambert MJ, Burger AG, Galeazzi RL, et al. Are selective increases in serum thyroxine (T4) due to iodinated inhibitors of T4 monodeiodination indicative of hyperthyroidism? J Clin Endocrinol Metab 1982;55(6):1058-65 (Pubitemid 13204245)
100. Sogol PB, Hershman JM, Reed AW, et al. The effects of amiodarone on serum thyroid hormones and hepatic thyroxine 5'-monodeiodination in rats. Endocrinology 1983;113(4):1464-9 (Pubitemid 13009161)
101. Chiovato L, Martino E, Tonacchera M, et al. Studies on the in vitro cytotoxic effect of amiodarone. Endocrinology 1994;134(5):2277-82 (Pubitemid 24142973)
102. Newman CM, Price A, Davies DW, et al. Amiodarone and the thyroid: a practical guide to the management of thyroid dysfunction induced by amiodarone therapy. Heart 1998;79(2):121-7 (Pubitemid 28157329)
103. Brennan MD, Erickson DZ, Carney JA, et al. Nongoitrous (type I) amiodarone-associated thyrotoxicosis: evidence of follicular disruption in vitro and in vivo. Thyroid 1995;5(3):177-83
104. Martino E, Aghini-Lombardi F, Lippi F, et al. Twenty-four hour radioactive iodine uptake in 35 patients with amiodarone associated thyrotoxicosis. J Nucl Med 1985;26(12):1402-7 (Pubitemid 16063020)
105. Cardenas GA, Cabral JM, Leslie CA. Amiodarone induced thyrotoxicosis: diagnostic and therapeutic strategies. Cleve Clin J Med 2003;70(7):624-6.8-31
106. Bartalena L, Grasso L, Brogioni S, et al. Serum interleukin-6 in amiodarone-induced thyrotoxicosis. J Clin Endocrinol Metab 1994;78(2):423-7 (Pubitemid 24061764)
107. Eaton SE, Euinton HA, Newman CM, et al. Clinical experience of amiodarone-induced thyrotoxicosis over a 3-year period: role of colour-flow Doppler sonography. Clin Endocrinol (Oxf) 2002;56(1):33-8 (Pubitemid 34107319)
108. Farwell AP, Abend SL, Huang SK, et al. Thyroidectomy for amiodarone-induced thyrotoxicosis. JAMA 1990;263(11):1526-8 (Pubitemid 20099048)
109. Jessurun GA, Crijns HJ. Amiodarone pulmonary toxicity. BMJ 1997;314(7081):619-20 (Pubitemid 27099873)
110. Rotmensch HH, Belhassen B, Swanson BN, et al. Steady-state serum amiodarone concentrations: relationships with antiarrhythmic efficacy and toxicity. Ann Intern Med 1984;101(4):462-9 (Pubitemid 14018040)
111. Polkey MI, Wilson PO, Rees PJ. Amiodarone pneumonitis: no safe dose. Respir Med 1995;89(3):233-5
112. Ott MC, Khoor A, Leventhal JP, et al. Pulmonary toxicity in patients receiving low-dose amiodarone. Chest 2003;123(2):646-51 (Pubitemid 36269460)
113. Camus P, Martin WJ II, Rosenow EC III. Amiodarone pulmonary toxicity. Clin Chest Med 2004;25(1):65-75 (Pubitemid 38296332)
114. Yamada Y, Shiga T, Matsuda N, et al. Incidence and predictors of pulmonary toxicity in Japanese patients receiving low-dose amiodarone. Circ J 2007;71(10):1610-16 (Pubitemid 47529665)
115. Martin WJ II, Rosenow EC III. Amiodarone pulmonary toxicity. Recognition and pathogenesis (Part 2). Chest 1988;93(6):1242-8
116. Martin WJ II, Rosenow EC III. Amiodarone pulmonary toxicity. Recognition and pathogenesis (Part I). Chest 1988;93(5):1067-75
117. Iskandar SB, Abi-Saleh B, Keith RL, et al. Amiodarone-induced alveolar hemorrhage. South Med J 2006r;99(4):383-7
118. Ashrafian H, Davey P. Is amiodarone an underrecognized cause of acute respiratory failure in the ICU? Chest 2001;120(1):275-82 (Pubitemid 32744890)
119. Saussine M, Colson P, Alauzen M, et al. Postoperative acute respiratory distress syndrome. A complication of amiodarone associated with 100 percent oxygen ventilation. Chest 1992;102(3):980-1
120. Marchlinski FE, Gansler TS, Waxman HL, et al. Amiodarone pulmonary toxicity. Ann Intern Med 1982;97(6):839-45 (Pubitemid 13240564)
121. Kuhlman JE, Teigen C, Ren H, et al. Amiodarone pulmonary toxicity: CT findings in symptomatic patients. Radiology 1990;177(1):121-5 (Pubitemid 20317333)
122. Jarand J, Lee A, Leigh R. Amiodaronoma: an unusual form of amiodarone-induced pulmonary toxicity. CMAJ 2007;176(10):1411-13 (Pubitemid 46762017)
123. Azzam I, Tov N, Elias N, et al. Amiodarone toxicity presenting as pulmonary mass and peripheral neuropathy: the continuing diagnostic challenge. Postgrad Med J 2006;82(963):73-5 (Pubitemid 43111809)
124. Berson A, De Beco V, Letteron P, et al. Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. Gastroenterology 1998;114(4):764-74 (Pubitemid 28160411)
125. Rigas B. The evolving spectrum of amiodarone hepatotoxicity. Hepatology 1989;10(1):116-17
126. Simon JB, Manley PN, Brien JF, et al. Amiodarone hepatotoxicity simulating alcoholic liver disease. N Engl J Med 1984;311(3):167-72 (Pubitemid 14092908)
127. Fogoros RN, Anderson KP, Winkle RA, et al. Amiodarone: clinical efficacy and toxicity in 96 patients with recurrent, drug-refractory arrhythmias. Circulation 1983;68(1):88-94 (Pubitemid 13058213)
128. Ingram DV, Jaggarao NS, Chamberlain DA. Ocular changes resulting from therapy with amiodarone. Br J Ophthalmol 1982;66(10):676-9 (Pubitemid 12018478)
129. Bockhardt H, Drenckhahn D, Lullmann-Rauch R. Amiodarone-induced lipidosis-like alterations in ocular tissues of rats. Albrecht Von Graefes Arch Klin Exp Ophthalmol 1978;207(2):91-6 (Pubitemid 8357376)
130. Ghosh M, McCulloch C. Amiodarone-induced ultrastructural changes in human eyes. Can J Ophthalmol 1984;19(4):178-86
131. Haug SJ, Friedman AH. Identification of amiodarone in corneal deposits. Am J Ophthalmol 1991;111(4):518-20
132. Harris L, McKenna WJ, Rowland E, et al. Side effects and possible contraindications of amiodarone use. Am Heart J 1983;106(4 Pt 2):916-23 (Pubitemid 13010826)
133. Kerin NZ, Aragon E, Faitel K, et al. Long-term efficacy and toxicity of highand low-dose amiodarone regimens. J Clin Pharmacol 1989;29(5):418-23 (Pubitemid 19143599)
134. Kaplan LJ, Cappaert WE. Amiodarone keratopathy. Correlation to dosage and duration. Arch Ophthalmol 1982;100(4):601-2 (Pubitemid 12136065)
135. Dolan BJ, Flach AJ, Peterson JS. Amiodarone keratopathy and lens opacities. J Am Optom Assoc 1985;56(6):468-70
136. Flach AJ, Dolan BJ, Sudduth B, et al. Amiodarone-induced lens opacities. Arch Ophthalmol 1983;101(10):1554-6 (Pubitemid 13010024)
137. Flach AJ, Dolan BJ. Progression of amiodarone induced cataracts. Doc Ophthalmol 1993;83(4):323-9 (Pubitemid 23280663)
138. Thystrup JD, Fledelius HC. Retinal maculopathy possibly associated with amiodarone medication. Acta Ophthalmol (Copenh) 1994;72(5):639-41 (Pubitemid 24370778)
139. D'Amico DJ, Kenyon KR, Ruskin JN. Amiodarone keratopathy: drug-induced lipid storage disease. Arch Ophthalmol 1981;99(2):257-61 (Pubitemid 11184137)
140. Nielsen CE, Andreasen F, Bjerregaard P. Amiodarone induced cornea verticillata. Acta Ophthalmol (Copenh) 1983;61(3):474-80 (Pubitemid 13102947)
141. Feiner LA, Younge BR, Kazmier FJ, et al. Optic neuropathy and amiodarone therapy. Mayo Clin Proc 1987;62(8):702-17 (Pubitemid 17118782)
142. Nazarian SM, Jay WM. Bilateral optic neuropathy associated with amiodarone therapy. J Clin Neuroophthalmol 1988;8(1):25-8
143. Mindel JS, Anderson J, Hellkamp A, et al. Absence of bilateral vision loss from amiodarone: a randomized trial. Am Heart J 2007;153(5):837-42 (Pubitemid 46602142)
144. Reifler DM, Verdier DD, Davy CL, et al. Multiple chalazia and rosacea in a patient treated with amiodarone. Am J Ophthalmol 1987;103(4):594-5
145. Miller RA, McDonald AT. Dermal lipofuscinosis associated with amiodarone therapy. Report of a case. Arch Dermatol 1984;120(5):646-9 (Pubitemid 14140284)
146. Zachary CB, Slater DN, Holt DW, et al. The pathogenesis of amiodarone-induced pigmentation and photosensitivity. Br J Dermatol 1984;110(4):451-6 (Pubitemid 14132493)
147. Bucknall CA, Keeton BR, Curry PV, et al. Intravenous and oral amiodarone for arrhythmias in children. Br Heart J 1986;56(3):278-84 (Pubitemid 16011159)
148. Charness ME, Morady F, Scheinman MM. Frequent neurologic toxicity associated with amiodarone therapy. Neurology 1984;34(5):669-71 (Pubitemid 14143528)